All Stories

  1. Towards an early clinical diagnosis of sporadic CJD VV2 (ataxic type)
  2. Prion Strain Characterization of a Novel Subtype of Creutzfeldt-Jakob Disease
  3. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels
  4. Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples
  5. Detection and Diagnosis of Prion Diseases Using RT-QuIC: An Update
  6. Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldt-Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma
  7. Erratum: Advanced tests for early and accurate diagnosis of Creutzfeldt–Jakob disease
  8. Cerebrospinal fluid real-time quaking-induced conversion is a robust and reliable test for sporadic creutzfeldt-jakob disease: An international study
  9. Advanced tests for early and accurate diagnosis of Creutzfeldt–Jakob disease
  10. Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings
  11. Detection of exosomal prions in blood by immunochemistry techniques
  12. A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk
  13. Rethinking of doxycycline therapy in Creutzfeldt-Jakob disease
  14. Synthetic Scrapie Infectivity: Interaction between Recombinant PrP and Scrapie Brain-Derived RNA
  15. Creutzfeldt–Jakob disease masked by head trauma and features of Wilson's disease
  16. The future for treating Creutzfeldt–Jakob disease
  17. Mutant PrPCJD prevails over wild-type PrPCJD in the brain of V210I and R208H genetic Creutzfeldt–Jakob disease patients
  18. A Test for Creutzfeldt–Jakob Disease Using Nasal Brushings
  19. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial
  20. Gerstmann-Sträussler-Scheinker Syndrome with Variable Phenotype in a New Kindred withPRNP-P102L Mutation
  21. Subtype-Specific Synaptic Proteome Alterations in Sporadic Creutzfeldt-Jakob Disease
  22. Assessment of prion reduction filters in decreasing infectivity of ultracentrifuged 263K scrapie-infected brain homogenates in “spiked” human blood and red blood cells
  23. Age at Death of Creutzfeldt-Jakob Disease in Subsequent Family Generation Carrying the E200K Mutation of the Prion Protein Gene
  24. Identification of Misfolded Proteins in Body Fluids for the Diagnosis of Prion Diseases
  25. Sporadic Creutzfeldt-Jakob disease subtype-specific alterations of the brain proteome: Impact on Rab3a recycling
  26. Role of proteomics in understanding prion infection
  27. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years
  28. Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD
  29. Editorial. The CNCCS, a benchmark Italian consortium for bioeconomy and an opportunity for the Istituto Superiore di Sanità
  30. Iatrogenic Creutzfeldt-Jakob Disease, Final Assessment
  31. Chronic wasting disease and atypical forms of bovine spongiform encephalopathy and scrapie are not transmissible to mice expressing wild-type levels of human prion protein
  32. Assessing Prion Infectivity of Human Urine in Sporadic Creutzfeldt-Jakob Disease
  33. Sensitivity to Biases of Case-Control Studies on Medical Procedures, Particularly Surgery and Blood Transfusion, and Risk of Creutzfeldt-Jakob Disease
  34. Sublethal Doses of β-Amyloid Peptide Abrogate DNA-dependent Protein Kinase Activity
  35. Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapie-infected brain homogenates in “spiked” albumin solutions
  36. In reply
  37. The pathological prion protein forms ionic conductance in lipid bilayer
  38. Corrigendum
  39. Transmission of sporadic Creutzfeldt-Jakob disease by blood transfusion: risk factor or possible biases
  40. Management and prevention of human prion diseases
  41. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease
  42. Clinical trials and methodological problems in prion diseases
  43. Incidence and spectrum of sporadic Creutzfeldt–Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification
  44. Proteomic profiling of PrP27-30-enriched preparations extracted from the brain of hamsters with experimental scrapie
  45. PrPTSE in muscle-associated lymphatic tissue during the preclinical stage of mice infected orally with bovine spongiform encephalopathy
  46. Efficacy of phthalocyanine tetrasulfonate against mouse-adapted human prion strains
  47. Prevalence of variant CJD in the UK
  48. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies
  49. Oral pravastatin prolongs survival time of scrapie-infected mice
  50. Genomic and post-genomic analyses of human prion diseases
  51. Neuroinvasion of the 263K scrapie strain after intranasal administration occurs through olfactory-unrelated pathways
  52. A novel PSEN2 mutation associated with a peculiar phenotype
  53. Survival in Alzheimer’s Disease Is Shorter in Women Carrying Heterozygosity at Codon 129 of the PRNP Gene and No APOE ε4 Allele
  54. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis
  55. Cyclooxygenase‐2, Prostaglandin E2, and Microglial Activation in Prion Diseases
  56. Recent Italian FFI Cases
  57. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation
  58. Inactivation of transmissible spongiform encephalopathy agents in food products by ultra high pressure–temperature treatment
  59. Efficient Transmission and Characterization of Creutzfeldt–Jakob Disease Strains in Bank Voles
  60. Pathological prion protein in muscles of hamsters and mice infected with rodent-adapted BSE or vCJD
  61. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity
  62. Genetic prion disease: the EUROCJD experience
  63. Migration of dendritic cells into the brain in a mouse model of prion disease
  64. Mortality from Human Transmissible Spongiform Encephalopathies: A Record Linkage Study
  65. Pre-symptomatic detection of prions by cyclic amplification of protein misfolding
  66. Trapping Prion Protein in the Endoplasmic Reticulum Impairs PrPCMaturation and Prevents PrPScAccumulation
  67. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies
  68. Standards for the assay of Creutzfeldt-Jakob disease specimens
  69. Prion (PrPres) Allotypes Profiling: New Perspectives from Mass Spectrometry
  70. Regulation of intrinsic prion protein by growth factors and tnf-α: the role of intracellular reactive oxygen species
  71. Ultra-high-pressure inactivation of prion infectivity in processed meat: A practical method to prevent human infection
  72. Mortality trend from sporadic Creutzfeldt-Jakob disease (CJD) in Italy, 1993–2000
  73. Detection of Pathologic Prion Protein in the Olfactory Epithelium in Sporadic Creutzfeldt–Jakob Disease
  74. Variant Creutzfeldt-Jakob disease in an Italian woman
  75. BSE and variant Creutzfeldt-Jakob disease: never say never
  76. Molecular diagnostics of transmissible spongiform encephalopathies
  77. A role for complement in transmissible spongiform encephalopathies
  78. Mutation of thePRNP gene at codon 211 in familial Creutzfeldt-Jakob disease
  79. WHO Consultation on Diagnostic Procedures for Transmissible Spongiform Encephalopathies: Need for Reference Reagents and Reference Panels
  80. Prion protein glycotype analysis in familial and sporadic Creutzfeldt-Jakob disease patients
  81. Expression of wild-type and V210I mutant prion protein in human neuroblastoma cells
  82. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease
  83. Ancestral Origins and Worldwide Distribution of the PRNP 200K Mutation Causing Familial Creutzfeldt-Jakob Disease
  84. Diagnosis of Creutzfeldt-Jakob disease
  85. High incidence of Creutzfeldt-Jakob disease in rural Calabria, Italy
  86. Alpha1 antichymotrypsin signal peptide polymorphism in sporadic Creutzfeldt–Jakob disease
  87. Highly Infectious Purified Preparations of Disease-Specific Amyloid of Transmissible Spongiform Encephalopathies Are Not Devoid of Nucleic Acids of Viral Size
  88. A new variant of Creutzfeldt-Jakob disease in the UK
  89. Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease
  90. Creutzfeldt-Jakob disease in Europe
  91. Tissue Handling in Suspected Creutzfeldt-Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases)
  92. Polymorphisms of the Prion Protein gene in italian patients with Creutzfeldt-Jakob disease
  93. Proteinase-resistant protein in human neuroblastoma cells infected with brain material from Creutzfeldt-Jakob patient
  94. Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease
  95. Small virus-like structure in brains from cases of sporadic and familial Creutzfeldt-Jakob disease
  96. Detection of proteinase-resistant protein (PrP) in small brain tissue samples from Creutzfeldt-Jakob disease patients
  97. Progressive Dementia in a Young Patient with a Homozygous Deletion of the PrP Gene.
  98. Incidence of Creutzfeldt-Jakob disease In Europe in 1993
  99. Characterisation of antisera raised against species-specific peptide sequences from scrapie-associated fibril protein and their application for post-mortem immunodiagnosis of spongiform encephalopathies
  100. Prions and related neurological diseases
  101. A new point mutation of the prion protein gene in Creutzfeldt-Jakob disease
  102. Creutzfeldt-Jakob disease after non-commercial dura mater graft
  103. Failure to Ameliorate Creutzfeldt-Jakob Disease with Amphotericin B Therapy
  104. Creutzfeldt-jakob disease in Italy
  105. Experimental drug treatment of scrapie: A pathogenetic basis for rationale therapeutics
  106. Combination Ultrafiltration and 6 MUrea Treatment of Human Growth Hormone Effectively Minimizes Risk from Potential Creutzfeldt-Jakob Disease Virus Contamination
  107. Amphotericin B: A Novel Class of Antiscrapie Drugs
  108. THE NUCLEUS BASALIS OF MEYNERT IN PARKINSONISM–DEMENTIA OF GUAM: A MORPHOMETRIC STUDY
  109. Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie
  110. A retrospective study of Creutzfeldt-Jakob disease in Italy (1972?1986)
  111. The scrapie agent and the prion hypothesis
  112. Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human Growth Hormone?
  113. Molecular forms of cholinesterases in CSF of Alzheimer's disease/senile dementia of Alzheimer type patients and matched neurological controls
  114. Serotoninergic System in Scrapie-Infected Hamsters
  115. Plasma levels of 13,14-dihydro-15-keto PGE2 after vaginal application of a new PGE2 film
  116. Isonicotinic hydrazide causes seizures in scrapie-infected hamstesr with shorter latency than in control animals: A possible GABAergic defect
  117. Choline acetyltransferase activity and [3H]quinuclidinylbenzilate binding in brains of scrapie-infected hamsters
  118. Ultrastructural studies in synaptic formations in dissociated fetal mouse brain cultures
  119. Peripheral neuropathy in the course of progressive systemic sclerosis: Light and ultrastructural study